Pre-Test Refractory/Resistant Multiple Myeloma: The Ever-Changing Therapeutic Landscape Pre-Test Which of the following approved agents is matched with its mechanism of action? Carfilzomib - inhibiting immune checkpoints PD-1 and PD-L1 and activity of T cells Ciltacabtagene autoleucel - nuclear accumulation of tumor suppressor proteins and inhibition of proto-oncogenic mRNA translation Isatuximab - irreversible binding to active sites of the 20S proteasome targets Teclistamab - targets CD3 on the surface of T cells and B-cell maturation antigen on the surface of myeloma cells Unsure A 63-year-old white male patient is refractory to lenalidomide and has had 4 prior lines of therapy. What is the preferred treatment? Ciltacabtagene autoleucel Monotherapy with teclistamab Selinexor-based regimen A or B A or C Unsure Which of the following is recommended to reduce AEs with talquetamab? Anticoagulation medication Antiemetics Mouth washes Zoledronic acid Unsure How confident are you in your ability to select appropriate first-line and second-line treatment options for multiple myeloma? Very Confident Confident Somewhat confident Not very confident Not at all confident
